{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"2.5","value":"1.3"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"4.4","value":"2.7"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"4.0","value":"2.6"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"4.3","value":"2.7"},{"groupId":"OG004","lowerLimit":"0.9","upperLimit":"8.9","value":"1.5"},{"groupId":"OG005","lowerLimit":"1.2","upperLimit":"2.1","value":"1.3"},{"groupId":"OG006","lowerLimit":"2.3","upperLimit":"6.5","value":"4.1"},{"groupId":"OG007","lowerLimit":"1.2","upperLimit":"3.0","value":"1.4"},{"groupId":"OG008","lowerLimit":"2.6","upperLimit":"4.3","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"105"}],"units":"Participants"}],"description":"Progression-free Survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation.\n\nProgressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"MEDIAN","populationDescription":"Treated patients with disease measurement","reportingStatus":"POSTED","timeFrame":"From the date of first infusion to the date of progression disease, death (of any cause), or last tumor evaluation, up to an average of 5 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}